Chen Li-Chia, Ashcroft Darren M
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
Headache. 2008 Feb;48(2):236-47. doi: 10.1111/j.1526-4610.2007.01007.x. Epub 2007 Dec 27.
To assess the relative efficacy and safety of zolmitriptan in the treatment of acute migraine attacks.
Zolmitriptan is a second-generation triptan developed for the treatment of migraine. Numerous randomized controlled trials (RCTs) have been carried out to compare different dosages and formulations of zolmitriptan against other treatments for acute migraine.
Random effects meta-analysis of 24 RCTs, including 15,408 patients suffering from acute migraine attacks. Subgroup analyses compared differences in response between different dosages and formulations of zolmitriptan, and other triptan comparators.
Zolmitriptan 2.5 mg tablet was found to be as effective as almotriptan 12.5 mg, eletriptan 40 mg, sumatriptan 50 mg and 100 mg and more effective than naratriptan 2.5 mg in terms of 2-hour pain-free rates. Likewise, zolmitriptan 5 mg tablet was as effective as sumatriptan 50 mg and 100 mg in 2-hour pain-free rates. Compared against zolmitriptan 2.5 mg tablet, eletriptan 80 mg was more effective in achieving headache relief, pain-free and sustained pain-free responses, and rizatriptan 10 mg was more effective in terms of sustained pain-free rates. Zolmitriptan 2.5 mg tablet was associated with a lower risk of adverse events than eletriptan 80 mg but higher risk than naratriptan 2.5 mg and rizatriptan 10 mg. Zolmitriptan 5 mg tablet was superior to zolmitriptan 2.5 mg tablet in achieving 1- and 2-hour pain-free response. There were no significant differences in 1- and 2-hour headache relief and adverse event rates between the different formulations of zolmitriptan 2.5 mg.
Zolmitriptan 2.5 mg tablet is an effective treatment for acute attacks of migraine showing similar efficacy to almotriptan 12.5 mg, eletriptan 40 mg, and sumatriptan 50 mg, and being more effective than naratriptan 2.5 mg in terms of pain-free response at 2 hours post dose. Zolmitriptan 2.5 mg tablet was also as effective as rizatriptan 10 mg in terms of headache relief and pain-free response but less effective in terms of sustained pain-free response.
评估佐米曲普坦治疗急性偏头痛发作的相对疗效和安全性。
佐米曲普坦是一种用于治疗偏头痛的第二代曲坦类药物。已经开展了大量随机对照试验（RCT），以比较佐米曲普坦不同剂量和剂型与其他急性偏头痛治疗方法的疗效。
对24项RCT进行随机效应荟萃分析，纳入15408例急性偏头痛发作患者。亚组分析比较了佐米曲普坦不同剂量和剂型与其他曲坦类对照药物在疗效上的差异。
就2小时无痛率而言，发现佐米曲普坦2.5毫克片剂与阿莫曲普坦12.5毫克、依立曲普坦40毫克、舒马曲普坦50毫克和100毫克疗效相当，且比那拉曲普坦2.5毫克更有效。同样，佐米曲普坦5毫克片剂在2小时无痛率方面与舒马曲普坦50毫克和100毫克疗效相当。与佐米曲普坦2.5毫克片剂相比，依立曲普坦80毫克在缓解头痛、达到无痛和持续无痛反应方面更有效，而利扎曲普坦10毫克在持续无痛率方面更有效。佐米曲普坦2.5毫克片剂的不良事件风险低于依立曲普坦80毫克，但高于那拉曲普坦2.5毫克和利扎曲普坦10毫克。佐米曲普坦5毫克片剂在实现1小时和2小时无痛反应方面优于佐米曲普坦2.5毫克片剂。佐米曲普坦2.5毫克的不同剂型在1小时和2小时头痛缓解及不良事件发生率方面无显著差异。
佐米曲普坦2.5毫克片剂是治疗偏头痛急性发作的有效药物，其疗效与阿莫曲普坦12.5毫克、依立曲普坦40毫克和舒马曲普坦50毫克相似，且在给药后2小时的无痛反应方面比那拉曲普坦2.5毫克更有效。佐米曲普坦2.5毫克片剂在缓解头痛和无痛反应方面也与利扎曲普坦10毫克相当，但在持续无痛反应方面效果较差。
